https://www.selleckchem.com/products/zk53.html
A previous randomized clinical trial concluded that an optimal concentration of 0.3% ropivacaine could provide satisfactory analgesia for breast cancer patients undergoing modified radical mastectomy. We wondered if a smaller volume (30 ml vs. 40 ml) of 0.3% ropivacaine could still provide adequate analgesia in an ultrasound-guided PECS II block in modified radical mastectomy. We performed a prospective parallel randomized double-blind controlled clinical trial. Eligible patients were assigned to either the P or P group (30 or 40 ml of 0.3
Curtir
Comentario
Compartilhar
